{"name":"Epoch Biosciences","slug":"epoch-bio","ticker":"Private","exchange":"Private","domain":"epochbio.com","description":"Epoch Biosciences is a private biotechnology company focused on gene therapy and genetic medicines. The company is developing treatments for various genetic disorders. With a strong pipeline and key products in development, Epoch Biosciences is positioning itself as a leader in the gene therapy market.","hq":"San Francisco, CA","founded":0,"employees":"","ceo":"Kiran Musunuru","sector":"Gene Therapy / Genetic Medicines","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"EB-101 patent cliff ($100M at risk)","drug":"EB-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"deal","headline":"Epoch Biosciences Closes $50M Series C Funding Round","summary":"Epoch Biosciences announced the closing of a $50 million Series C funding round to support the development of its gene therapy pipeline.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"trial","headline":"Epoch Biosciences Initiates Phase 1/2 Clinical Trial for EB-101","summary":"Epoch Biosciences initiated a Phase 1/2 clinical trial for EB-101, its gene therapy candidate for the treatment of epidermolysis bullosa.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2004-11-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2004","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2004-10-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"EB-101","drugSlug":"epidermolysis-bullosa-gene-therapy","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Spark Therapeutics","Bluebird Bio","Editas Medicine"],"therapeuticFocus":["Gene Therapy","Genetic Disorders"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}